FDAsafety guidance72% confidence
Drug Trials Snapshots: ZYCUBO
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Daiichi Sankyo.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiovascular · Atherosclerosis
- Sub-indication
- General
Related signal: Daiichi Sankyo Trials Triple Therapy for Coronary Atherosclerosis Without Events